

# The Impact of Inter-Center Competition on Liver Transplant Practices and Outcomes

Jeff Halldorson M.D.
Associate Professor
Transplant Surgery
UCSD Department of Surgery

# Liver Allocation Proceeds by "Sickest First" Principle

Acute "Fulminant" Liver
Failure (Expected
Lifespan <7 days
without
Transplantation)

Status 1
Highest Priority

**Chronic Liver Failure** 

or

Waitlist Mortality Priority based on MELD score

### MELD and Waitlist Mortality





Figure 2. Box plots of mortality risk on the waiting list, by MELD score.

Merion, RM Liver Transplantation. 2004

# Liver Transplant Waitlist



### Transplant Center Report Card

#### Center 1


| Post-transplant Outcomes ( 01/01/2009-06/30/2011)        | 1 Year   |          |  | Tal |
|--|----------|----------|--|-----|
|  | Observed | Expected | Statistical Significance of Difference |     |
| Adult graft survival (based on 301 transplants) (%)      | 90.46    | 87.15    | Statistically Higher (b)               |     |
| Adult patient survival (based on 295 transplants) (%)    | 91.36    | 89.83    | Not Significantly Different (a)        |     |
| Pediatric graft survival (based on 35 transplants) (%)   | 85.71    | 87.37    | Not Significantly Different (a)        |     |
| Pediatric patient survival (based on 31 transplants) (%) | 93.55    | 93.43    | Not Significantly Different (a)        |     |

#### Center 2


| Post-transplant Outcomes ( 01/01/2009-06/30/2011)    | 1 Year   |          |   |  |  |
|--|----------|----------|---|--|--|
|  | Observed | Expected | Statistical Significance<br>of Difference |  |  |
| Adult graft survival (based on 33 transplants) (%)   | 75.00    | 89.41    | Statistically Lower (b)                   |  |  |
| Adult patient survival (based on 31 transplants) (%) | 79.84    | 92.29    | Statistically Lower (b)                   |  |  |
| Pediatric graft survival (%)                         | NA       | NA       | NA  |  |  |
| Pediatric patient survival (%)                       | NA       | NA       | NA  |  |  |


### vvaitiist/ i ranspiants/Deaths by Year

WAITING LIST: National liver-transplant statistics show that many people die while waiting for donor organs.



# The Changing Liver Donor Population 1989-2009





1989

2009

No ECD Donors

No Matching considerations Necessary

No Special Informed Consent

### The Older Donor European Challenges

Mario Angelico M.D.




Fig. 1.

Age distribution of overall donor population. Continuous line: estimated normal density (mean = 52.9, SD = 18.9). Dashed line: empirical density (kernel estimate).

The Bad News: Donor age will continue to increase

The Good News: There is a great potential in the US to expand utilization of older donors for Liver Transplantation


#### Donor Risk Index

#### Characteristics Associated with Liver Graft Failure

**Table 3:** Donor factors significantly associated with liver allograft failure (1998–2002)\*

| Donor parameter                   | RR   | 95% CI      | p-Value  |
|-----------------------------------|------|-------------|----------|
| Age                               |      |             |          |
| <40                               | 1.00 |             |          |
| 40—49                             | 1.17 | 1.08-1.26   | 0.0002   |
| 50-59                             | 1.32 | 1.21-1.43   | < 0.0001 |
| 60-69                             | 1.53 | 1.39-1.68   | < 0.0001 |
| >70                               | 1.65 | 1.46-1.87   | < 0.0001 |
| African-American race (vs White)  | 1.19 | 1.10-1.29   | < 0.0001 |
| Donor height (per 10 cm decrease) | 1.07 | 1.04-1.09   | < 0.0001 |
| COD = CVA                         | 1.16 | 1.08-1.24   | < 0.0001 |
| $COD = Other^{\dagger}$           | 1.20 | 1.03-1.40   | 0.018    |
| DCD                               | 1.51 | 1.19-1.91   | 0.0006   |
| Partial/Split                     | 1.52 | 1.27 – 1.83 | < 0.0001 |

# Liver Transplant Waitlist



# Organ Acceptance Decisions in Liver Transplantation: Howard Model





Figure 4: Accept and Reject Regions in Howard [2002] Model

## Matching Donors and Recipients



<u>Lee KW</u>, <u>Simpkins CE</u>, <u>Montgomery RA</u>, <u>Locke JE</u>, <u>Segev DL</u>, <u>Maley WR</u>. <u>Factors affecting graft survival after liver transplantation from donation after <u>cardiac</u> death donors. Transplantation 2006; 82: 1683-8</u>

# Organ Acceptance Decisions in Liver Transplantation: Alagosz Model





Figure 5: Alternative Accept and Reject Regions

### Matching Donors and Recipients:

#### "Window of Appropriate Use"



\*DCD, Split, Older Donor.....Steatosis

### On competition... Adam Smith

In general, if any branch of trade...... be advantageous to the public, the freer and more general the competition, it will always be the more so.

The Wealth Of Nations, Book II, Chapter II, p.329, para. 106.

**Hypothesis:** "Local Competition Between Liver Transplant Centers Within a DSA should Advantage the Public"


- 1. Improved Outcomes
- 2. Greater Access/Improved Organ Utilization
- 3. Decreased Cost

# Distribution of Liver Transplant Centers

#### **UNOS** Regions



#### DSAs/Centers




The competitive environment for organs varies greatly at the local level. (1-6 Liver Centers/DSA)

# Overall Patient Survival Non-Competitive(NC) vs. Competitive(C) Centers

|                          | NC(22%) | C(78%) | p-value |
|--------------------------|---------|--------|---------|
| 1 year actual Survival   | 88.0%   | 85.3%  | <0.001  |
| 1 year expected Survival | 88.3%   | 86.4%  | <0.001  |
|                          |         |        |         |
| 3 year actual Survival   | 80.8%   | 76.5%  | <0.001  |
| 3 year expected Survival | 80.2%   | 77.4%  | <0.001  |


2003-2010

#### 3 Year Patient Survival MELD era (n=375 observations)



| Centers/DSA | Mean  |   |   |   |
|-------------|-------|---|---|---|
| I           | 82.4% | A |   |   |
| 3           | 79.3% | A | В |   |
| 2           | 77.2% |   | В |   |
| 6           | 76.2% |   | В | C |
| 4           | 75.8% |   | В | Ç |
| 5           | 72.3% |   |   | C |

Student's t \a=0.01



| Centers/DSA | Mean  |   |   |   |
|-------------|-------|---|---|---|
| I           | 80.5% | A |   |   |
| 2           | 78.2% |   | В |   |
| 3           | 77.3% |   | В | C |
| 4           | 76.2% |   |   | Ç |
| 6           | 75.8% |   |   | C |
| 5           | 75.5% |   |   | C |

| ogObs -<br>logExp | Difference log Ofference log Actual - log Expected -0.7 - 0.9 - 0.7 - 0.9 - 1.1 - 0.9 - 1.1 - 0.9 - 1.1 - 0.9 - 1.1 - 0.9 - 1.1 - 0.9 - 1.1 - 0.9 - 1.1 - 0.9 - 1.1 - 0.9 - 1.1 - 0.9 - 1.1 - 0.9 - 1.1 - 0.9 - 1.1 - 0.9 - 1.1 - 0.9 - 0.9 - 1.1 - 0.9 - 0.9 - 1.1 - 0.9 - 0. | ŧ |   | 1 | _ | ‡    | ~     | ************************************** | - | • | _< | • | •                                |
|-------------------|--|---|---|---|---|------|-------|--|---|---|----|---|----------------------------------|
|                   | -1.3 ┴   | 1 | ' | 2 | , | Gent | ers/I | osa<br>Osa                             |   | 5 | ,  | 6 | Each Pair<br>Student's t<br>0.01 |

| Centers/DSA | Mean   |   |   |
|-------------|--------|---|---|
| 3           | 0.024  | A |   |
| I           | 0.021  | A |   |
| 6           | 0.000  | A | В |
| 4           | -0.010 | A | В |
| 2           | -0.017 | A | В |
| 5           | -0.058 |   | В |

# What is the Impact of Competitive Environment on?

- 1. Post Transplant Outcomes?
- 2. Organ Utilization?
- 3. Disease Severity at Transplantation
- 4. Listing/Organ acceptance

### Methods

All liver transplants from the MELD era (2003 and 2009) were studied using the UNOS database (n=38,385). Competitive environment for a local market was stratified into tertiles using the **Herfindahl–Hirschman Index\* (HHI).** 


Herfindahl–Hirschman Index (HHI) a commonly accepted measure of market concentration. The HHI is calculated by squaring the market share of each firm competing in the market and then summing the resulting numbers.

**Example 1**: A market consisting of four centers with shares of 30%, 30%, 20% and 20%, the HHI =  $2,600 (30^2 + 30^2 + 20^2 + 20^2)$ .

**Example 2**: A market consisting of three centers with shares of 90%, 7% and 3%, the HHI =  $8158 (90^2 + 7^2 + 3^2)$ .


**Example 3**: A market consisting of a single center. HHI=10,000 (100<sup>2</sup>)

### Distribution of HHI







### Post Transplant Survival and Competition



### Recipient Risk and Competition


#### Transplant MELD vs. HHI






### Donor Risk and Competition


DRI vs. HHI



#### **DRI Quartile by Competitive Group**



# Listed/Transplanted Ratio and Competition



Listed/Transplanted Ratio

Oity 2.5

1.5

1.5

1.000 3000 5000 7000 9000 11000 HHI

Listed/p.m.p and Transplanted/p.m.p. by HHI tertile

Listed/Transplanted ratio by HHI (OPO Center Data)

# Impact of Competition Univariate and Multivariate Analysis

|                           |      | Univariate |         |      | Multivariate |         |
|---------------------------|------|------------|---------|------|--------------|---------|
| Risk of patient death (D) |      |            |         |      |              |         |
| Characteristic            | HR   | 95% CI     | p-value | HR   | 95% CI       | p-value |
| HHI tertile               |      |            |         |      |              |         |
| 1 (low comp, >0.57)       | 1.00 |            |         | 1.00 |              |         |
| 2 (mid comp, 0.38-0.57)   | 1.05 | 1.00-1.11  | 0.037   | 1.04 | 0.99-1.09    | 0.133   |
| 3 (high comp, <0.38)      | 1.23 | 1.18-1.29  | <0.001  | 1.04 | 0.99-1.10    | 0.119   |

Comparison of donor and recipient characteristics by DSA competition level (described by HHI tertile) (characteristics significant in SRTR reports.)

# Competition for Limited Resources in Liver Transplantation

**Poorer Outcomes** 

Increased Disease Severity/
Resource Utilization and Cost

Adam Smith??

Greatly Improved Access to Listing

Small Improvement In Access to Transplantation

# "Tragedy of the Commons"

"We can make little progress ... until we explicitly exorcize the spirit of Adam Smith, ... the idea that an individual who "intends only his own gain," is, "led by an invisible hand to promote ... the public interest"

Garritt Hardin, Science Dec. 13, 1968

Hardin's Example: Herdsman sharing a common pasture are each individually motivated to add more cattle to their herd. The result is an overgrazed common in which the animals starve.

Two Dead Since Arizona Medicaid Program Slashed Transplant Coverage




# Proposed Mechanism: Match List Competition

| No Competition | Equal Competition | Dominant Competitor |
|----------------|-------------------|---------------------|
| Α              | A                 | A                   |
| Α              | В                 | В                   |
| Α              | C                 | A                   |
| Α              | D                 | A                   |
| Α              | E                 | Α                   |
| Α              | A                 | Α                   |
| Α              | В                 | Α                   |
| A              | C                 | Α                   |
| A              | D                 | В                   |
| Absence of     | Under C           | ompetition          |

Absence of Competition Accept "Best Match"

Under Competition
Accept
"Maximum Tolerated
Risk"

### Donor/Recipient Matching in Liver Transplantation, the Advantage of List Dominance (ECD Donor)




#### Outcome vs. Market Position


MC=Monopoly Center, EC=Equal-Competitor, DC Dominant Competitor, NDC Non-Dominant Competitor

Observed 3 Year Patient Survival

Expected 3 Year Patient Survival

Observed/Expected





# Competition, Utilization, and MELD

#### Less Competition

More Competition



- -Opportunity for better control of Donor/Recipient Risk and Matching
- -Decreased Access to listing
- -Risk Aversion/Decreased Utilization

- -Inability to control match risk for both donors and recipients
- -Poorer Outcomes/Higher Cost in "Sickest First" Paradigm

# What Should We Compete For?

How do we Avoid a "Race to the Bottom" in "Sickest first" Allocation?

Is it time for the Liver transplant community to better balance utility against disease severity in allocation policy?

What can be done on a local level to mitigate the negative influence of competition

# Acknowledgements

John Roberts M.D., UCSF
Jennifer Dodge M.S., UCSF
Harry Paarsch, Ph.D., University of Melbourne
Alberto Segre Ph.D., University of Iowa